Tsai et al. [31] and Tseng et al. [32] studies demonstrated that the activation of MKK3/6-p38MAPK signaling pathway by Etoposide (VP-16) [30] or paclitaxel [31] is involved in the increased expression of Excision repair cross-complementary 1 (ERCC1) in A549, H1975 [31] and H1650, H1703 [32] NSCLC lines respectively, driving survival and resistance to DNA damage agents. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.